---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-012538"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2023-04-17T23:59:59+00:00"
generated_at: "2026-06-17T01:18:00.605057+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INVO Bioscience reports 2022 revenue $0.8M, cash $0.1M; EBITDA loss widens to $(8.4)M

## Summary
- FY 2022 revenue $822K (up 40% excl. Ferring license); Q4 revenue $278K, up 18% sequentially.
- Adjusted EBITDA loss of $(8.4)M vs $(2.8)M in 2021; includes $0.3M acquisition costs and IP write-down.
- Cash $0.1M at Dec 31, 2022; $3.0M gross raised in March 2023 registered direct offering.
- Signed binding agreement to acquire Wisconsin Fertility Institute for $10M payable over 3 years; expected close Q2 2023.
- Clinic revenue from all centers up 726% to $1.6M; Atlanta center contributed $614K.

## SEC filing metadata
- accession: 0001493152-23-012538
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2023-04-17T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000149315223012538/0001493152-23-012538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000149315223012538/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-012538
- JSON: https://secwatch.observer/filing/0001493152-23-012538.json
- Plain text: https://secwatch.observer/filing/0001493152-23-012538.txt

## Key facts
- Earnings Releases
  INVO Fertility, Inc. reported fourth quarter ended December 31, 2022 results: revenue $278,142.
  - Period: fourth quarter ended December 31, 2022
  - Revenue: $278,142
  - Result: reported results
  source text: Q4 2022 Financial Highlights (all metrics compared to Q4 2021 unless otherwise noted) ● Revenue was $278,142, compared to $12,532 (excluding license revenue), and was up 18% sequentially compared to the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315223012538/0001493152-23-012538-index.htm
- Earnings Releases
  INVO Fertility, Inc. reported year ended December 31, 2022 results: revenue $822,196.
  - Period: year ended December 31, 2022
  - Revenue: $822,196
  - Result: reported results
  source text: 2022 Financial Highlights (all metrics compared to 2021 unless otherwise noted) ● Revenue increased 40% to $822,196 compared to $588,687 (excluding license revenue) in the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1417926/000149315223012538/0001493152-23-012538-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.